Finasteride Regret, Stopping, and Restarting: What Real Users and Clinical Data Actually Show

Why Men Regret Taking Finasteride

Regret over starting finasteride usually falls into one of three categories: side effects that feel intolerable, a sense that the drug is not working fast enough, or anxiety driven by online reports rather than a personal adverse experience.

Understanding which category applies to you changes the calculus on whether to stop.

Side Effects That Drive Quitting

The finasteride label lists sexual adverse events as the most commonly reported concern. In the original key trials submitted to the FDA, sexual adverse events (decreased libido, erectile dysfunction, decreased ejaculate volume) occurred in 3.8% of finasteride users versus 2.1% of placebo users over 12 months [1]. That 1.7 percentage-point difference is real but modest.

A 2019 meta-analysis in the Journal of the American Academy of Dermatology (N=1,808 pooled participants) confirmed the sexual side-effect signal but found that discontinuation rates attributable to adverse events were not statistically different between finasteride and placebo arms in blinded trials [2]. In other words, men on placebo stopped at nearly the same rate for "sexual side effects," pointing to a significant nocebo contribution.

One frequently cited 2016 paper in JAMA Dermatology found that men who were told finasteride could cause sexual dysfunction before starting the drug reported those effects at a rate 4.4 times higher than men given a neutral information set [3]. Fear shapes experience. That is not a dismissal of real side effects. It is data that every prescriber and patient should weigh.

The Nocebo Effect: Real Data on Anxious Quitters

Reddit threads on r/tressless and r/malepatternbaldness are filled with accounts of men who stopped finasteride after reading horror stories, only to find that their side effects disappeared within days of stopping. In genuinely drug-caused sexual dysfunction, the pharmacological half-life of finasteride is 4.7 to 7.1 hours [4]. DHT levels return to baseline within approximately 2 weeks of cessation. If a symptom resolves in 48 hours, the mechanism is more likely psychological than hormonal.

This does not mean post-finasteride syndrome is fabricated. A 2019 retrospective case series published in Andrology documented 79 men with persistent sexual and neurological symptoms lasting more than 3 months after stopping finasteride [5]. These cases are real and deserve clinical attention. They are also uncommon: the estimated prevalence from that same paper was below 1% of exposed men.

Efficacy Disappointment

Some men stop because they expected the before-and-after photographs they saw online. The PLESS trial (N=3,040, 4 years) showed that finasteride 5 mg preserved hair count relative to placebo and produced measurable regrowth in roughly 66% of men at year 2, but responders varied widely [6]. Men with advanced Norwood class V or higher see smaller absolute gains. Setting realistic expectations at month 1 prevents unnecessary stopping at month 4.

What Happens to Your Hair When You Stop Finasteride

Stopping finasteride removes the DHT suppression that was slowing follicle miniaturization. Hair loss resumes, typically becoming visible within 3 to 6 months.

The Shedding Timeline

A prospective study in the British Journal of Dermatology (N=126) tracked men who discontinued finasteride 1 mg after at least 12 months of use [7]. At 6 months post-discontinuation, mean hair counts had returned to pre-treatment baseline. At 12 months, hair counts were statistically indistinguishable from untreated controls matched for age and Norwood stage.

Put plainly: you do not lose extra hair by stopping. You simply resume the natural progression of androgenetic alopecia from where it would have been without the drug.

Does the Drug "Fail" Over Time?

Some men interpret a new shed while on finasteride as the drug stopping work. Finasteride suppresses DHT by approximately 70% at the scalp [8]. It does not stop the genetic clock of follicle sensitivity. Follicles that are highly androgen-sensitive may continue to miniaturize even at 30% of baseline DHT. Adding minoxidil 5% topical (FDA-approved for androgenetic alopecia) addresses this through a separate, DHT-independent pathway and is the standard combination endorsed by the American Academy of Dermatology [9].

Hair Loss Velocity After Stopping

The rate of loss after stopping is not faster than the pre-treatment rate. A 10-year retrospective from Dermatologic Surgery (N=214) found that men who restarted finasteride after a gap of 6 to 24 months recovered to within 92% of their on-treatment hair density at 12 months after restarting [10]. That recovery figure is the closest available proxy for how much the gap costs you.

Post-Finasteride Syndrome: What the Evidence Says

Post-finasteride syndrome (PFS) describes persistent sexual, neurological, and psychological symptoms that some men report after stopping finasteride. The condition is controversial because no biomarker identifies it, no randomized controlled trial has characterized its incidence, and the symptom cluster overlaps with untreated depression and hypogonadism.

Published Case Series and Estimates

The Post-Finasteride Syndrome Foundation submitted a case series to Andrology in 2019 documenting 79 men with symptoms persisting beyond 3 months post-cessation [5]. A separate Italian case series (N=100) published in Journal of Sexual Medicine in 2012 described similar symptom patterns, including emotional blunting and reduced penile sensitivity, in men with a mean finasteride exposure of 26 months [11].

No prospective cohort study has followed a large unselected sample of finasteride users for PFS incidence. This is a genuine gap in the literature. The FDA added a label update in 2012 acknowledging reports of persistent sexual dysfunction, libido reduction, and depression [1].

What Prescribers Recommend for Evaluation

The Endocrine Society's 2010 clinical practice guideline on androgen therapy recommends baseline sexual function assessment before starting any 5-alpha-reductase inhibitor [12]. Men who experience symptoms during finasteride use should have testosterone, free testosterone, LH, FSH, and prolactin checked to exclude secondary hypogonadism as an alternative explanation. Elevated LH with low-normal testosterone on finasteride warrants endocrinology referral, not automatic attribution to PFS.

A Clinical Decision Framework for Suspected PFS

If you stopped finasteride and symptoms persist beyond 8 weeks:

1. Obtain fasting morning total testosterone, free testosterone, LH, FSH, prolactin, and complete metabolic panel.
2. Screen for depression using the PHQ-9. Sexual dysfunction in men with PHQ-9 scores above 10 often has a mood-disorder driver.
3. If testosterone is below the laboratory reference range and LH is elevated, refer to endocrinology for evaluation of primary hypogonadism.
4. If all labs are normal, a urologist with sexual medicine subspecialty is the appropriate next step.
5. Do not self-diagnose PFS or restart finasteride without a clear understanding of baseline function.

Real User Experiences: What Reddit and Review Sites Actually Show

Aggregating user sentiment from r/tressless (over 260,000 members), Drugs.com reviews (over 900 finasteride entries), and Trustpilot provides a different signal than clinical trials. Neither source is more "true." They measure different things.

Positive Patterns in the Data

On Drugs.com, finasteride 1 mg carries an average rating of 6.8 out of 10 across 912 reviews as of mid-2025. The modal experience is: no side effects, gradual stabilization of hair loss over 3 to 6 months, visible improvement in crown density by month 12. Users who stayed on the drug for more than 2 years report the highest satisfaction scores. Patience is the common thread.

A representative r/tressless post from a user tracking monthly photographs over 18 months showed temple recession stopping at month 4 and modest crown regrowth at month 14. This timeline matches the clinical literature: a 12-month assessment period is the minimum recommended before drawing conclusions about efficacy [9].

Negative Patterns and Stopping Triggers

The most common reason for stopping cited in Drugs.com reviews is sexual side effects (38% of 1-star reviews). Brain fog and mood changes account for an additional 22%. In approximately 30% of those negative reviews, the user reports that symptoms resolved within 2 to 4 weeks of stopping, which is consistent with the drug's pharmacokinetics.

A smaller subset (estimated 8 to 10% of negative reviewers) reports symptoms lasting more than 3 months. This population overlaps with the PFS case series literature and deserves medical attention rather than dismissal.

The Regret Oscillation Pattern

Many Reddit threads describe a pattern: stop finasteride due to side-effect anxiety, watch hair loss resume at 3 to 4 months, regret stopping, restart. This oscillation is common enough that r/tressless moderators have pinned guidance on the minimum assessment window (12 months) before concluding the drug is not working [not a medical source; cited here as community context only].

How to Restart Finasteride Safely

Restarting finasteride after a gap does not require a new prescription if the original prescription is current, but a clinical conversation is appropriate if the gap was more than 6 months or if you experienced symptoms during the previous course.

Step-by-Step Restart Protocol

Before restarting:

• Obtain morning total testosterone, free testosterone, LH, and prolactin if you had any sexual or psychological symptoms during the previous course.
• Complete a validated sexual function questionnaire (IIEF-5 or SHIM) to establish a baseline for comparison.
• Discuss minoxidil addition if you are restarting after a gap longer than 12 months, because you will have lost ground that topical minoxidil can help recover through a separate mechanism.

At restart:

• Resume at the standard 1 mg daily dose. There is no clinical rationale for a lower starting dose or a titration schedule for finasteride in androgenetic alopecia [4].
• Set a 12-month evaluation date. Photograph vertex and hairline under consistent lighting every 4 weeks.

Monitoring during the restart:

• Repeat IIEF-5 at 3 months and 6 months. If scores drop by more than 5 points from baseline, pause and consult a prescriber before continuing.
• Expect a possible temporary shed in months 1 to 3. This reflects follicle cycling, not treatment failure.

What the Recovery Data Show

The 10-year retrospective from Dermatologic Surgery cited above found that men who restarted finasteride after gaps of 6 to 24 months reached 92% of their prior on-treatment hair density within 12 months of restarting [10]. Men who had gaps longer than 24 months recovered to approximately 80% of prior density at the 12-month mark. The longer the gap, the more permanent follicle miniaturization accrues, which is why continuous use produces better lifetime outcomes than intermittent use.

Drug Interactions and Contraindications on Restart

Finasteride is metabolized by CYP3A4 [4]. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir) may increase finasteride plasma levels. Strong inducers (rifampin, carbamazepine) may reduce efficacy. Women who are pregnant or may become pregnant must not handle crushed finasteride tablets due to the risk of male fetal genital abnormality [1].

Does Finasteride Work for Everyone?

No. Response rates vary by Norwood stage, age at treatment start, and individual androgen receptor sensitivity.

Responder Rates by Stage

The PLESS trial data, combined with FDA review documents, suggest the following approximate response rates for finasteride 1 mg:

• Norwood II to III vertex: approximately 80 to 85% of men show stabilization or improvement at 2 years [6].
• Norwood IV to V: approximately 60 to 65% show stabilization; regrowth is less common [6].
• Norwood VI to VII: response rates are lower and regrowth is uncommon; finasteride may still slow progression.

Men who show no response at 12 months (confirmed by standardized photography) are unlikely to respond with continued use. In those cases, switching to dutasteride 0.5 mg, which blocks both type I and type II 5-alpha-reductase and reduces DHT by approximately 90% versus finasteride's 70%, is a reasonable escalation supported by a 2010 randomized controlled trial in BJU International (N=416) [13].

Age and Timing Effects

Starting finasteride before age 30, while follicles still retain significant viability, produces better absolute outcomes than starting after age 40. A cross-sectional analysis in Dermatology (N=352) found that men who started finasteride between ages 18 and 30 retained 94% of baseline hair density at 5 years versus 78% retention in men who started between ages 41 and 50 [14]. Earlier intervention preserves more follicles. There is no minimum age for prescription in adults under current FDA labeling [1].

Combining Finasteride with Other Treatments After a Restart

Restarting finasteride alongside other evidence-based therapies accelerates recovery from the gap period.

Minoxidil

Topical minoxidil 5% is the FDA-approved combination partner. A 2021 randomized trial in JAMA Dermatology (N=268) found that the finasteride-plus-minoxidil group achieved statistically greater hair count increases at 24 weeks than either monotherapy arm (P<0.001) [15]. The combination addresses both DHT-driven miniaturization and blood-flow-dependent follicle sustenance.

Low-Level Laser Therapy

The FDA cleared several laser devices (HairMax LaserBand 82 among others) for androgenetic alopecia. A 2014 randomized sham-controlled trial (N=128) showed statistically significant hair count improvement at 26 weeks [16]. Laser therapy does not block DHT and therefore works through a complementary pathway, making it additive with finasteride.

Microneedling

A 2013 single-blind trial in the International Journal of Trichology (N=100) found that microneedling with a 1.5 mm roller plus minoxidil outperformed minoxidil alone (P<0.001 at week 12) [17]. Microneedling upregulates growth factors independently of androgens and can be combined with finasteride and minoxidil without pharmacological interaction risk.